The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

Dr. Yifan Jian explores the evolution of OCT, challenges in retinal imaging, and AI's potential in biophotonics, shaping the ...

Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET. Company Participants. Douglas Onsi - President ...

Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth ...

Medically reviewed by Danielle Weiss, MD Diabetic macular edema (DME) is a leading cause of vision loss in people with ...

During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations ...

Ended Q4 with $168.1M of cash and cash equivalents and believes current cash will support current and planned operations into 2026. “In ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024.

Hyundai ADM Bio (KOSDAQ symbol 187660) announced on the 24th that its first-in-class pseudo-resistance-targeting agent, ...

John L. Marshall, MD, discusses the impact of the SUNLIGHT trial in patients with refractory metastatic colorectal cancer.